INBX – inhibrx biosciences, inc. (US:NASDAQ)

News

Inhibrx Biosciences (INBX) was upgraded by Zacks Research to "hold".
Inhibrx Biosciences (INBX) was downgraded by Wall Street Zen from "ho
Inhibrx Biosciences (INBX) is now covered by Stifel Nicolaus. They set a "buy" rating and a $150.00 price target on the stock.
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results [Yahoo! Finance]
Inhibrx Biosciences GAAP EPS of -$2.11 misses by $0.03 [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com